Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
No aliases recorded.
Dabrafenib, sold under the brand name Tafinlar among others, is an anti-cancer medication used for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth.
Read the full article on WikipediaUnresectable Stage III or Stage IV malignant melanoma Clinical criteria: Treatment Phase: Continuing treatment Patient must have previously been issued with an authority prescription for this drug, AND Patient must have stable or responding disease. Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.
Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma Clinical criteria: Treatment Phase: Initial treatment The treatment must be adjuvant to complete surgical resection, AND The condition must be positive for a BRAF V600 mutation, AND Patient must have a WHO performance status of 1 or less, AND Patient must be receiving PBS-subsidised trametinib and dabrafenib concomitantly for this condition, AND Patient must not have received prior PBS-subsidised treatment for this condition, AND The treatment must commence within 12 weeks of complete resection, AND Patient must not receive more than 12 months of combined PBS-subsidised and non-PBS-subsidised adjuvant therapy. Treatment criteria: Must be treated by a medical practitioner.
Paediatric high grade glioma Clinical criteria: Treatment Phase: Initial treatment The condition must be World Health Organisation (WHO) grade 3 or 4, AND The condition must be positive for a BRAF V600 mutation, AND Patient must have either a: (i) Karnofsky, (ii) Lansky performance score of at least 50%, AND Patient must have relapsed or progressed following frontline therapy; OR Patient must have failed to respond to frontline therapy, AND Patient must be receiving PBS-subsidised trametinib and dabrafenib concomitantly for this condition. Population criteria: Patient must have been aged between 12 months to 18 years at diagnosis.
Paediatric low grade glioma Clinical criteria: Treatment Phase: Initial treatment The condition must be World Health Organisation (WHO) grade 1 or 2, AND The condition must have progressed following surgical excision; OR The condition must not be amenable to surgery with risk of neurological impairment following progression, AND The condition must be positive for a BRAF V600 mutation, AND Patient must have either a: (i) Karnofsky, (ii) Lansky performance score of at least 50%, AND Patient must be receiving PBS-subsidised trametinib and dabrafenib concomitantly for this condition. Population criteria: Patient must have been aged between 12 months to 18 years at diagnosis.
Stage IV (metastatic) non-small cell lung cancer (NSCLC) Clinical criteria: Patient must have/have had a WHO performance status of no greater than 2 at treatment initiation with this drug for this condition, AND The condition must be positive for a BRAF V600E mutation, AND Patient must be receiving trametinib and dabrafenib concomitantly for this condition. Treatment criteria: Patient must be undergoing initial treatment with this drug; OR Patient must be undergoing continuing treatment with this drug, with an absence of further disease progression while being treated with this drug; OR Patient must be undergoing non-PBS-subsidised treatment with this drug for this PBS indication, with an absence of further disease progression since commencing non-PBS-subsidised supply.
Working under the parallel aged-care framework? Aged-care equivalent →